(Q35890470)

10 August 2017

1 reference

title

Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls (English)

1 reference

10 August 2017

0 references

2

Lyle L Moldawer

1 reference

10 August 2017

Douglas J Minnich

1

1 reference

10 August 2017

publication date

1 August 2004

1 reference

Proceedings of the Nutrition Society

10 August 2017

published in

1 reference

10 August 2017

volume

63

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

437-441

1 reference

Genetic markers in sepsis

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Why immunomodulatory therapies have not worked in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

The epidemiology of sepsis in the United States from 1979 through 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Multiple organ failure--the discrepancy between our scientific knowledge and understanding and the management of our patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Shock and tissue injury induced by recombinant human cachectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Pathophysiologic basis of sepsis: considerations for future strategies of intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1079%2FPNS2004378

21 January 2018

Identifiers

DOI

10.1079/PNS2004378

1 reference

10 August 2017

1 reference